Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Topotecan hydrochloride (NSC609699) 是一种具有抗癌活性的拓扑异构酶I 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 413 | 现货 | ||
25 mg | ¥ 590 | 现货 | ||
50 mg | ¥ 1,080 | 现货 | ||
100 mg | ¥ 1,790 | 现货 | ||
500 mg | ¥ 4,250 | 现货 | ||
1 g | ¥ 5,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 315 | 现货 |
产品描述 | Topotecan hydrochloride (NSC609699) is an antineoplastic agent used to treat ovarian cancer. |
靶点活性 | Topo I (DU-145 Luc cells):2 nM, Topo I (MCF-7 Luc cells):13 nM |
体外活性 | Topotecan在严重联合免疫缺陷的人预后不良ALL小鼠模型中,诱发有效的抗白血病活性.在全身性药物暴露水平下,Topotecan显著增加了用另外致命剂量的humaln白血病细胞攻击的SCID小鼠的无病存活.神经胶质瘤优先表达TRAIL R2,用Topotecan治疗明显上调其表达.皮下接种DU-145 Luc细胞然后用Topotecan处理,通过尾铗和发光成像测定,肿瘤显著生长和消退. |
体内活性 | Topotecan在耐辐射的人B系急性淋巴细胞性白血病细胞中,稳定拓扑异构酶I/DNA可裂解复合物,尽管bcl-2蛋白高度表达,也能够引起快速的细胞凋亡,并且以剂量依赖方式抑制急性淋巴细胞性白血病细胞的克隆生长。Topotecan对DU-145 Luc和MCF-7 Luc细胞具有更强的药物活性。Topotecan在DNA复制期间,通过稳定拓扑异构酶I和DNA之间的共价复合物,并防止酶联单链DNA断裂后再连接,引起细胞毒性。 |
细胞实验 | Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager. (Only for Reference) |
别名 | SKF 104864A, SKFS 104864A, NSC609699, Nogitecan HCl, NSC 609669, 盐酸拓扑替康, Topotecan HCl |
分子量 | 457.92 |
分子式 | C23H24ClN3O5 |
CAS No. | 119413-54-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 45.8 mg/mL (100 mM)
DMSO: 45.8 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.1838 mL | 10.9189 mL | 21.8379 mL | 54.5947 mL |
5 mM | 0.4368 mL | 2.1838 mL | 4.3676 mL | 10.9189 mL | |
10 mM | 0.2184 mL | 1.0919 mL | 2.1838 mL | 5.4595 mL | |
20 mM | 0.1092 mL | 0.5459 mL | 1.0919 mL | 2.7297 mL | |
50 mM | 0.0437 mL | 0.2184 mL | 0.4368 mL | 1.0919 mL | |
100 mM | 0.0218 mL | 0.1092 mL | 0.2184 mL | 0.5459 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Topotecan hydrochloride 119413-54-6 Apoptosis Autophagy DNA Damage/DNA Repair Topoisomerase SKF 104864A NSC609669 SKFS 104864A NSC609699 NSC-609699 Inhibitor Nogitecan HCl NSC 609669 NSC 609699 NSC-609669 Topotecan Hydrochloride 盐酸拓扑替康 inhibit Topotecan HCl Topotecan inhibitor